Takeda prepping to take over EU production of stem cell therapy from 2021

Image: iStock/unoL

Takeda says it is assessing manufacturing options ahead of potential European approval later this year of the Crohn’s disease stem cell therapy licensed from TiGenix.

Pfizer site in McPherson, Kansas

US FDA rejects Pfizer's Epogen biosimilar citing McPherson site warning


ImmunoCellular Therapeutics halts brain cancer cell therapy trial due to lack of cash

Image: iSoctk/Professor25

EMA committee gives Samsung Bioepis nod for Humira biosimilar Imraldi

Image: iStock/Artfoliophoto

Protein A resin maker teams on continuous and column-free chromatography tech

Image: iStock/boonsom

Brazilian plant to make Humira biosimilar in 'tobacco-based bioreactors'

BIO 2017 is being held in San Diego, California. Image: iStock/Mindy_Nicole_Photography

Ex-PM David Cameron tells BIO 2017 not to worry about Brexit effect on employees

See More Headlines

Markets & Regulations


Patient deaths end Seattle Genetics leukaemia Phase III trial


Wuxi Biologics IPO in Hong Kong brings in $511m


The World Bank invests in Indian Biopharma

See More in Markets & Regulations

Upstream Processing


TxCell hires Lentigen to make vectors used to produce its organ rejection cell therapy


Single-use in Ireland on the up? GE Healthcare, Thermo Fisher and NIBRT discuss the trend


Thermo Fisher opens single-use tech testing centre in UK

See More in Upstream Processing

Downstream Processing


Sanofi outlines €600m biologics manufacturing investment plan


Keeping it in the family: Rentschler to offer fill and finish services

Source Google maps

US FDA clears BioMarin to make $380,000-a year Vimizim in Ireland

See More in Downstream Processing

Bio Developments


Germany’s Merck invests in immune-oncology in Switzerland

Image: iStock/cgtoolbox

Cell Medica buys T cell receptor cancer candidate from UK Catapult


Aimmune to make peanut allergy candidate in Florida, US

See More in Bio Developments

Popular News

Image: iStock/boonsom

Brazilian plant to make Humira biosimilar in 'tobacco-based bioreactors'


Merck & Co pauses two Ph III Keytruda studies after patient deaths


Sanofi outlines €600m biologics manufacturing investment plan




Latest Products

See more products